Prelude Capital Management’s BioDelivery Sciences International, Inc. BDSI Stock Holding History

Prelude Capital Management’s Portfolio BDSI Stock Details BDSI Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2015 Q3	–	Sell	-12,000	Closed	-$96K	–	2100
2015 Q2	$96K	Buy	+12,000	New	+$103K	0.01%	902
2014 Q3	–	Sell	-7,000	Closed	-$84K	–	2438
2014 Q2	$84K	Buy	7,000 +2,000	+40%	+$19K	0.01%	1170
2014 Q1	$42K	Buy	+5,000	New	+$40.4K	0.01%	1369

Other funds holding BDSI

Deerfield Management New York $8.48B AUM 99.04% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

NCM

Nantahala Capital Management New Canaan, Connecticut $2.72B AUM 121.58% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Wasatch Advisors Salt Lake City, Utah $15.3B AUM 25.06% 1-Year Est. Return

SFM

Systematic Financial Management Teaneck, New Jersey $4.36B AUM 40.56% 1-Year Est. Return

RCMNY

Rubric Capital Management (New York) New York $9.44B AUM 68.42% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Nuveen Charlotte, North Carolina $369B AUM 31.66% 1-Year Est. Return

Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return

Prelude Capital Management's BDSI Position: Q1 2020 in Review

Prelude Capital Management sold out of BioDelivery Sciences International, Inc. (BDSI) in Q1 2020, closing a stake of 13,900 shares — an estimated $88K sold.

Prelude Capital Management first reported a position in BDSI in Q4 2013 and held it in 15 quarters. The position peaked at $691K in Q2 2015. 153 funds tracked by Wall St. Rank hold BDSI as of Q1 2020.

Prelude Capital Management reported no remaining BioDelivery Sciences International, Inc. position as of Q1 2020 after selling out during the quarter.
Prelude Capital Management sold 13,900 BioDelivery Sciences International, Inc. shares in Q1 2020, an estimated $88K.
Prelude Capital Management first reported a position in BioDelivery Sciences International, Inc. in Q4 2013 and held it in 15 quarters.
Prelude Capital Management's BioDelivery Sciences International, Inc. position peaked at $691K in Q2 2015.
153 funds tracked by Wall St. Rank held BioDelivery Sciences International, Inc. as of Q1 2020.

Based on Prelude Capital Management's 13F filing for Q1 2020, filed 15 May 2020.